Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroblastoma 19Lung Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Ganglioneuroblastoma 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Penile Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Keratosis, Actinic 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1

Interventions

lutetium Lu 177 dotatate 15Everolimus 11Nivolumab 10pembrolizumab 9Temozolomide 9Capecitabine 7cabozantinib 6Sunitinib 6lenvatinib 5lanreotide 4gallium Ga 68 dotatate 4Ipilimumab 4Etoposide 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3pazopanib 3avelumab 3Octreotide 3Magnetic Resonance Spectroscopy 3Injections 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3surufatinib 2sintilimab 2fosbretabulin 2fludarabine 2Specimen Handling 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroendocrine Tumors × Isotretinoin × Clear all
NCT01048086 2016-06-21

90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

University of Iowa

Phase 2 Withdrawn
CNSEndocrineNET

Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡